Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | BRS3 | P32247 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2548788 | 0.87 | ALDH1A1 (0.51) | TAAR1ALDH1A1PKMAGTR1AGTR2 | |
| SCHEMBL2979131 | 0.81 | TAAR1 (0.59) | TAAR1ALDH1A1PKML3MBTL1 | |
| SCHEMBL1845528 | 0.81 | MAPT (0.50) | — | |
| SCHEMBL1844573 | 0.80 | SOS1 (0.59) | PKMAGTR1AGTR2 | |
| SCHEMBL1839656 | 0.80 | ALDH1A1 (0.47) | TAAR1ALDH1A1PKML3MBTL1 | |
| SCHEMBL1841582 | 0.76 | ALDH1A1 (0.43) | TAAR1ALDH1A1PKML3MBTL1 | |
| SCHEMBL2551563 | 0.75 | AGTR1 (0.47) | AGTR1AGTR2 | |
| SCHEMBL21199185 | 0.73 | SOS1 (0.58) | TAAR1ALDH1A1PKML3MBTL1 | |
| SCHEMBL1840296 | 0.70 | BRS3 (0.48) | AGTR1AGTR2BRS3 | |
| SCHEMBL11957619 | 0.70 | SOS1 (0.58) | ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236843-B2 | Anti inflammatory compounds | ELDER PHARMACEUTICALS LTD. (IN) | 2012-08-07 | — | — | US | claimed |
| US-20110263543-A1 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2011-10-27 | — | — | US | claimed |
| EP-2321281-A2 | ANTI INFLAMMATORY COMPOUNDS | Elder Pharmaceuticals Ltd (IN) | 2011-05-18 | — | — | EP | claimed |
| WO-2010029576-A2 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2010-03-18 | — | — | WO | claimed |
| US-8236843-B2 | Anti inflammatory compounds | ELDER PHARMACEUTICALS LTD. (IN) | 2012-08-07 | — | — | US | disclosed |
| US-8236843-B2 | Anti inflammatory compounds | ELDER PHARMACEUTICALS LTD. (IN) | 2012-08-07 | — | — | US | disclosed |
| US-8236843-B2 | Anti inflammatory compounds | ELDER PHARMACEUTICALS LTD. (IN) | 2012-08-07 | — | — | US | disclosed |
| US-20110263543-A1 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2011-10-27 | — | — | US | disclosed |
| US-20110263543-A1 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2011-10-27 | — | — | US | disclosed |
| US-20110263543-A1 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2011-10-27 | — | — | US | disclosed |
| EP-2321281-A2 | ANTI INFLAMMATORY COMPOUNDS | Elder Pharmaceuticals Ltd (IN) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010029576-A2 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010029576-A2 | ANTI INFLAMMATORY COMPOUNDS | ELDER PHARMACEUTICALS LTD. (IN) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263543-A1 | ANTI INFLAMMATORY COMPOUNDS | IL1B, LITAF, IL6 | TAAR1 3754/4885ALDH1A1 197/4885PKM 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.